Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 73% Improvement Relative Risk ICU admission 67% c19early.org/d Charkowick et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 208 patients in the USA (January 2020 - February 2021) Lower mortality (p=0.016) and ICU admission (p=0.001) Charkowick et al., AJRCCM Conference Favors vitamin D Favors control
Vitamin D Deficiency and Thrombosis in Hospitalized SARS-CoV-2 Patients with Suspected Pulmonary Embolism
Charkowick et al., AJRCCM Conference
Charkowick et al., Vitamin D Deficiency and Thrombosis in Hospitalized SARS-CoV-2 Patients with Suspected Pulmonary Embolism, AJRCCM Conference
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 208 hospitalized COVID+ patients in the USA, showing vitamin D deficiency associated with higher mortality and ICU admission.
risk of death, 73.4% lower, OR 0.27, p = 0.02, high D levels 140, low D levels 68, adjusted per study, inverted to make OR<1 favor high D levels, multivariable, RR approximated with OR.
risk of ICU admission, 67.2% lower, OR 0.33, p = 0.001, high D levels 140, low D levels 68, adjusted per study, inverted to make OR<1 favor high D levels, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Charkowick et al., 5 May 2022, retrospective, USA, peer-reviewed, 10 authors, study period 1 January, 2020 - 5 February, 2021.
Contact: scharkowick@usf.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: C62 EXPANDING OUR INSIGHT INTO COVID-19 / Thematic Poster Session / Tuesday, May 17/09:30 AM-03:45 PM / Area D, Hall F (North Building, Exhibition Level), Moscone Center Vitamin D Deficiency and Thrombosis in Hospitalized SARS-CoV-2 Patients with Suspected Pulmonary Embolism S. V. Charkowick, C. N. Logothetis, A. Jordan, C. Hanna, S. Zhang, K. Tsay, E. Coughlin, R. Mhaskar, T. A. Weppelmann, A. Oxner; USF Health Morsani College of Medicine, Tampa, FL, United States. Corresponding author's email: scharkowick@usf.edu RATIONALE Despite the use of anticoagulation therapy in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are high rates of pulmonary embolism (PE) and deep vein thrombosis (DVT). Vitamin D is a potent immunomodulator with anticoagulative properties that may play a role in suppressing the formation of thrombotic emboli. Supplementation with vitamin D has an excellent safety profile and provides protection against acute respiratory infections. Recent studies have indicated that there is a positive association between vitamin D deficiency and the severity of SARS-CoV-2. However, the relationship between vitamin D deficiency and the incidence of thrombotic events in patients with SARS-CoV-2 has not been thoroughly investigated. The main objective of this study was to evaluate the association between vitamin D deficiency and thrombotic events (PE or DVT) in hospitalized SARS-CoV-2 patients. METHODS This was a retrospective, cross-sectional study including 208 hospitalized SARS-CoV-2 patients who received a computed tomographic pulmonary angiography (CTPA) based on clinical suspicion of PE between January 1, 2020, and February 5, 2021. A serum vitamin D level of <20 ng/mL was used to categorize vitamin D deficiency. Nonparametric tests and multivariate binary logistic regression were used to evaluate the association between serum vitamin D level at hospital admission and the incidence of thrombotic events. Several other clinical outcomes (intensive care unit (ICU) admission, mechanical ventilation, and mortality) were also analyzed. RESULTS The mean vitamin D level at hospital admission was 26.7±13.0 ng/mL (N=208). Approximately one-third of patients had vitamin D deficiency (n=68, 32.7%). No relationship was found between vitamin D deficiency and the occurrence of thrombotic events. The incidence of PE was 19.1% in vitamin D deficient patients and 11.4% in vitamin D sufficient patients (p=0.13). The incidence of DVT was 8.6% in vitamin D deficient patients and 9.6% in vitamin D sufficient patients (p=0.46). After adjusting for confounders, vitamin D deficiency was positively correlated with admission to the ICU (OR 3.047, 95% CI 1.57-5.91, p=0.001) and overall mortality (OR 3.76, 95% CI 1.29-11.01, p=0.016). Vitamin D deficiency was not associated with the need for mechanical ventilation. CONCLUSIONS This study found no significant associations between vitamin D deficiency and thrombotic events or the need for mechanical ventilation in hospitalized SARS-CoV-2 patients. Patients with vitamin D deficiency were more likely to be admitted to the ICU and had increased overall mortality. This abstract is funded by: USF Health Morsani College of Medicine Am J Respir Crit Care Med 2022;205:A4571 Internet address: www.atsjournals.org Online Abstracts Issue
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit